Morgan Stanley
NVLN

Morgan Stanley’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Morgan Stanley’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,680
Closed -$1K – 6966
2019
Q3 		$1K Buy
2,680
+1,763
+192% +$1.28K ﹤0.01% 6610
2019
Q2 		$0 Sell
917
-627
-41% -$697 ﹤0.01% 6868
2019
Q1 		$2K Sell
1,544
-1,295
-46% -$1.48K ﹤0.01% 6492
2018
Q4 		$3K Sell
2,839
-1,627,631
-100% -$1.84M ﹤0.01% 6394
2018
Q3 		$4.83M Buy
1,630,470
+17,260
+1% +$61.1K ﹤0.01% 3216
2018
Q2 		$5.94M Buy
1,613,210
+3,032
+0.2% +$12.2K ﹤0.01% 2953
2018
Q1 		$5.63M Buy
1,610,178
+418,200
+35% +$1.77M ﹤0.01% 2898
2017
Q4 		$3.72M Buy
1,191,978
+70,470
+6% +$339K ﹤0.01% 3417
2017
Q3 		$7.88M Buy
1,121,508
+603,391
+116% +$4.84M ﹤0.01% 2518
2017
Q2 		$4.78M Buy
518,117
+461,831
+821% +$4.45M ﹤0.01% 2889
2017
Q1 		$604K Buy
56,286
+54,743
+3,548% +$559K ﹤0.01% 4722
2016
Q4 		$13K Buy
+1,543
New +$13.7K ﹤0.01% 6108

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Morgan Stanley's NVLN Position: Q4 2019 in Review

Morgan Stanley sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 2,680 shares — an estimated $1K sold.

Morgan Stanley first reported a position in NVLN in Q4 2016 and held it in 12 quarters. The position peaked at $7.88M in Q3 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Morgan Stanley reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Morgan Stanley sold 2,680 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $1K.
  • Morgan Stanley first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 12 quarters.
  • Morgan Stanley's Novelion Therapeutics Inc. Common Shares position peaked at $7.88M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Morgan Stanley's 13F filing for Q4 2019, filed 14 Feb 2020.